论文部分内容阅读
目的探讨腹腔温热灌注化疗治疗腹膜腔转移肿瘤的临床疗效和不良反应。方法选取2011年1月至2012年1月间收治的腹膜腔转移肿瘤患者82例,随机分为对照组和观察组,对照组患者单纯采用静脉化疗,观察组患者采用腹腔温热灌注化疗,比较两组患者临床疗效和不良反应发生情况。结果观察组患者有效率为65.9%,明显高于对照组的43.9%,两组差异有统计学意义(P<0.05);观察组患者不良反应发生率均明显低于对照组,两组差异有统计学意义(P<0.05)。结论腹腔温热灌注化疗治疗腹膜腔转移肿瘤疗效显著,可杀灭腹腔游离癌细胞,改善患者预后,且不良反应少,安全有效,值得临床推广和应用。
Objective To investigate the clinical efficacy and adverse reactions of intraperitoneal hyperthermic perfusion chemotherapy in the treatment of peritoneal metastases. Methods Eighty-two patients with peritoneal metastases who were treated between January 2011 and January 2012 were randomly divided into control group and observation group. Patients in control group were treated with intravenous chemotherapy alone. Patients in observation group were treated with intraperitoneal hyperthermic perfusion chemotherapy. Two groups of patients with clinical efficacy and adverse reactions. Results The effective rate of the observation group was 65.9%, which was significantly higher than that of the control group (43.9%), the difference between the two groups was statistically significant (P <0.05). The incidence of adverse reactions in the observation group was significantly lower than that in the control group Statistical significance (P <0.05). Conclusion Intraperitoneal hyperthermic perfusion chemotherapy for the treatment of peritoneal metastasis of tumor significant effect, can kill peritoneal free cancer cells to improve the prognosis of patients with less adverse reactions, safe and effective, worthy of clinical promotion and application.